دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Are Intraarticular Glucocorticoids Safe in Osteoarthritis?
Joel A. Block
doi : 10.1002/art.42032
Volume 74, Issue 2 p. 181-183
Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis
Elizabeth Park,Jan Griffin,Joan M. Bathon
doi : 10.1002/art.41979
Volume 74, Issue 2 p. 184-199
Rheumatoid arthritis (RA) patients have almost twice the risk of heart failure (HF) as individuals without RA, even with adjustment for the presence of ischemic heart disease. Moreover, RA patients remain at a 2-fold higher risk of mortality from HF compared to non–RA patients. These observations suggest that RA-specific inflammatory pathways are significant contributors to this increased risk of HF. Herein we summarize the epidemiology of HF in RA patients, the differences in myocardial structure or function between RA patients and non–RA patients without clinical signs of HF, and data on the role of systemic and local inflammation in RA HF pathophysiology. We also discuss the impact of subduing inflammation through the use of RA disease-modifying therapies on HF and myocardial structure and function, emphasizing gaps in the literature and areas needing further research.
Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti–Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti–Tumor Necrosis Factor on B Cells
Nida Meednu,Jennifer Barnard,Kelly Callahan,Andreea Coca,Bethany Marston,Ralf Thiele,Darren Tabechian,Marcy Bolster,Jeffrey Curtis,Meggan Mackay,Jonathan Graf,Richard Keating,Edwin Smith,Karen Boyle,Lynette Keyes-Elstein,Beverly Welch,Ellen Goldmuntz,Jennifer H. Anolik
doi : 10.1002/art.41941
Volume 74, Issue 2 p. 200-211
B cells can become activated in germinal center (GC) reactions in secondary lymphoid tissue and in ectopic GCs in rheumatoid arthritis (RA) synovium that may be tumor necrosis factor (TNF) and lymphotoxin (LT) dependent. This study was undertaken to characterize the peripheral B cell compartment longitudinally during anti-TNF therapy in RA.
Activation of Hypothalamic AMP-Activated Protein Kinase Ameliorates Metabolic Complications of Experimental Arthritis
Patricia Seoane-Collazo,Eva Rial-Pensado,Ánxela Estévez-Salguero,Edward Milbank,Lucía García-Caballero,Marcos Ríos,Laura Liñares-Pose,Morena Scotece,Rosalía Gallego,José Manuel Fernández-Real,Rubén Nogueiras,Carlos Diéguez,Oreste Gualillo,Miguel López
doi : 10.1002/art.41950
Volume 74, Issue 2 p. 212-222
To investigate whether thermogenesis and the hypothalamus may be involved in the physiopathology of experimental arthritis (EA).
Clinical Images: The appearance of scurvy on magnetic resonance imaging
Sami Giryes,Daniela Militianu,Yolanda Braun-Moscovici
doi : 10.1002/art.41932
Volume 74, Issue 2 p. 222-222
Progression of Knee Osteoarthritis With Use of Intraarticular Glucocorticoids Versus Hyaluronic Acid
Justin Bucci,Xiaoyang Chen,Michael LaValley,Michael Nevitt,James Torner,Cora E. Lewis,David T. Felson
doi : 10.1002/art.42031
Volume 74, Issue 2 p. 223-226
To determine whether intraarticular glucocorticoid (GC) injections are associated with increased knee osteoarthritis (OA) progression compared to hyaluronic acid (HA) injections, which have been reported to delay OA progression and knee replacement.
Association of Increased Serum Lipopolysaccharide, But Not Microbial Dysbiosis, With Obesity-Related Osteoarthritis
Richard F. Loeser,Liubov Arbeeva,Kathryn Kelley,Anthony A. Fodor,Shan Sun,Veronica Ulici,Lara Longobardi,Yang Cui,Delisha A. Stewart,Susan J. Sumner,M. Andrea Azcarate-Peril,R. Balfour Sartor,Ian M. Carroll,Jordan B. Renner,Joanne M. Jordan,Amanda E. Nelson
doi : 10.1002/art.41955
Volume 74, Issue 2 p. 227-236
To test the hypothesis that an altered gut microbiota (dysbiosis) plays a role in obesity-associated osteoarthritis (OA).
Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case–Control Study
Yael Shalev Rosenthal,Naama Schwartz,Iftach Sagy,Lev Pavlovsky
doi : 10.1002/art.41946
Volume 74, Issue 2 p. 237-243
To investigate the effect of biologic treatments for psoriasis on the incidence of psoriatic arthritis (PsA).
Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System
Laetitia Penso,Christina Bergqvist,Antoine Meyer,Philippe Herlemont,Alain Weill,Mahmoud Zureik,Rosemary Dray-Spira,Emilie Sbidian
doi : 10.1002/art.41923
Volume 74, Issue 2 p. 244-252
To investigate whether the initiation of treatment with an interleukin-17 inhibitor (IL-17i) in real life is associated with a higher risk of inflammatory bowel disease (IBD) in patients who had both psoriasis (PsO) and psoriatic arthritis (PsA)/ankylosing spondylitis (AS).
Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis
David Simon,Koray Tascilar,Arnd Kleyer,Sara Bayat,Eleni Kampylafka,Maria V. Sokolova,Ana Zekovic,Axel J. Hueber,Jürgen Rech,Louis Schuster,Klaus Engel,Michael Sticherling,Georg Schett
doi : 10.1002/art.41239
Volume 74, Issue 2 p. 253-262
To test whether the presence of structural entheseal lesions in psoriasis patients influences the risk of progression to psoriatic arthritis (PsA).
Clinical Images: Diffuse systemic sclerosis, skin bleaching, and telangiectasia
Cindy Flower
doi : 10.1002/art.41921
Volume 74, Issue 2 p. 262-262
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis
Nathalie E. Chalhoub,Scott E. Wenderfer,Deborah M. Levy,Kelly Rouster-Stevens,Amita Aggarwal,Sonia I. Savani,Natasha M. Ruth,Thaschawee Arkachaisri,Tingting Qiu,Angela Merritt,Karen Onel,Beatrice Goilav,Raju P. Khubchandani,Jianghong Deng,Adriana R. Fonseca,Stacy P. Ardoin,Coziana Ciurtin,Ozgur Kasapcopur,Marija Jelusic,Adam M. Huber,Seza Ozen,Marisa S. Klein-Gitelman,Simone Appenzeller,André Cavalcanti,Lampros Fotis,Sern Chin Lim,Rodrigo M. Silva,Julia Ramírez- Miramontes,Natalie L. Rosenwasser,Claudia Saad-Magalhaes,Dieneke Schonenberg-Meinema,Christiaan Scott,Clovis A. Silva,Sandra Enciso,Maria T. Terreri,Alfonso-Ragnar Torres-Jimenez,Maria Trachana,Sulaiman M. Al-Mayouf,Prasad Devarajan,Bin Huang,Hermine I. Brunner,for the Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Work Group and the Pediatric Rheumatology European Society Lupus Working Party
doi : 10.1002/art.41930
Volume 74, Issue 2 p. 263-273
To develop a standardized steroid dosing regimen (SSR) for physicians treating childhood-onset systemic lupus erythematosus (SLE) complicated by lupus nephritis (LN), using consensus formation methodology.
Association of a Combination of Healthy Lifestyle Behaviors With Reduced Risk of Incident Systemic Lupus Erythematosus
May Y. Choi,Jill Hahn,Susan Malspeis,Emma F. Stevens,Elizabeth W. Karlson,Jeffrey A. Sparks,Kazuki Yoshida,Laura Kubzansky,Karen H. Costenbader
doi : 10.1002/art.41935
Volume 74, Issue 2 p. 274-283
While previous studies have demonstrated an association between individual factors related to lifestyle and the risk of systemic lupus erythematosus (SLE), it is unclear how the combination of these factors might affect the risk of incident SLE. This study was undertaken to prospectively evaluate whether a combination of healthy lifestyle factors is associated with a lower risk of incident SLE and its subtypes (anti–double-stranded DNA [anti-dsDNA]–positive and anti-dsDNA–negative SLE).
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV-2 Vaccination
Peter M. Izmirly,Mimi Y. Kim,Marie Samanovic,Ruth Fernandez-Ruiz,Sharon Ohana,Kristina K. Deonaraine,Alexis J. Engel,Mala Masson,Xianhong Xie,Amber R. Cornelius,Ramin S. Herati,Rebecca H. Haberman,Jose U. Scher,Allison Guttmann,Rebecca B. Blank,Benjamin Plotz,Mayce Haj-Ali,Brittany Banbury,Sara Stream,Ghadeer Hasan,Gary Ho,Paula Rackoff,Ashira D. Blazer,Chung-E Tseng,H. Michael Belmont,Amit Saxena,Mark J. Mulligan,Robert M. Clancy,Jill P. Buyon
doi : 10.1002/art.41937
Volume 74, Issue 2 p. 284-294
To evaluate seroreactivity and disease flares after COVID-19 vaccination in a multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE).
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
Alessandra Bettiol,Maria Letizia Urban,Lorenzo Dagna,Vincent Cottin,Franco Franceschini,Stefano Del Giacco,Franco Schiavon,Thomas Neumann,Giuseppe Lopalco,Pavel Novikov,Chiara Baldini,Carlo Lombardi,Alvise Berti,Federico Alberici,Marco Folci,Simone Negrini,Renato Alberto Sinico,Luca Quartuccio,Claudio Lunardi,Paola Parronchi,Frank Moosig,Georgina Espígol-Frigolé,Jan Schroeder,Anna Luise Kernder,Sara Monti,Ettore Silvagni,Claudia Crimi,Francesco Cinetto,Paolo Fraticelli,Dario Roccatello,Angelo Vacca,Aladdin J. Mohammad,Bernhard Hellmich,Maxime Samson,Elena Bargagli,Jan Willem Cohen Tervaert,Camillo Ribi,Davide Fiori,Federica Bello,Filippo Fagni,Luca Moroni,Giuseppe Alvise Ramirez,Mouhamad Nasser,Chiara Marvisi,Paola Toniati,Davide Firinu,Roberto Padoan,Allyson Egan,Benjamin Seeliger,Florenzo Iannone,Carlo Salvarani,David Jayne,Domenico Prisco,Augusto Vaglio,Giacomo Emmi,on behalf of the European EGPA Study Group
doi : 10.1002/art.41943
Volume 74, Issue 2 p. 295-306
Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4?weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4?weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4?weeks and 300 mg every 4?weeks in a large European EGPA cohort.
Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific Clones
Salome Glauzy,Brennan Olson,Christopher K. May,Daniele Parisi,Christopher Massad,James E. Hansen,Changwan Ryu,Erica L. Herzog,Eric Meffre
doi : 10.1002/art.41927
Volume 74, Issue 2 p. 307-317
Early selection steps preventing autoreactive naive B cell production are often impaired in patients with autoimmune diseases, but central and peripheral B cell tolerance checkpoints have not been assessed in patients with systemic sclerosis (SSc). This study was undertaken to characterize early B cell tolerance checkpoints in patients with SSc.
Platelet Phagocytosis via P-selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis
Angelo A. Manfredi,Giuseppe A. Ramirez,Cosmo Godino,Annalisa Capobianco,Antonella Monno,Stefano Franchini,Enrico Tombetti,Sara Corradetti,Jörg H. W. Distler,Marco E. Bianchi,Patrizia Rovere-Querini,Norma Maugeri
doi : 10.1002/art.41926
Volume 74, Issue 2 p. 318-328
It is unclear why activated platelets and platelet-derived microparticles (MPs) accumulate in the blood of patients with systemic sclerosis (SSc). This study was undertaken to investigate whether defective phagocytosis might contribute to MP accumulation in the blood of patients with SSc.
Expansion of Fc? Receptor IIIa–Positive Macrophages, Ficolin 1–Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis
Dan Xue,Tracy Tabib,Christina Morse,Yi Yang,Robyn T. Domsic,Dinesh Khanna,Robert Lafyatis
doi : 10.1002/art.41813
Volume 74, Issue 2 p. 329-341
In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.
Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort
Matteo Bianchi,Sergey V. Kozyrev,Antonella Notarnicola,Lina Hultin Rosenberg,Åsa Karlsson,Pascal Pucholt,Simon Rothwell,Andrei Alexsson,Johanna K. Sandling,Helena Andersson,Robert G. Cooper,Leonid Padyukov,Anna Tjärnlund,Maryam Dastmalchi,The ImmunoArray Development Consortium,The DISSECT Consortium,Jennifer R. S. Meadows,Louise Pyndt Diederichsen,Øyvind Molberg,Hector Chinoy,Janine A. Lamb,Lars Rönnblom,Kerstin Lindblad-Toh,Ingrid E. Lundberg
doi : 10.1002/art.41929
Volume 74, Issue 2 p. 342-352
Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of complex autoimmune conditions characterized by inflammation in skeletal muscle and extramuscular compartments, and interferon (IFN) system activation. We undertook this study to examine the contribution of genetic variation to disease susceptibility and to identify novel avenues for research in IIMs.
Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1
Deborah L. Stone,Amanda Ombrello,Juan I. Arostegui,Corinne Schneider,Vinh Dang,Adriana de Jesus,Charlotte Girard-Guyonvarc'h,Cem Gabay,Wonyong Lee,Jae Jin Chae,Ivona Aksentijevich,Raphaela T. Goldbach-Mansky,Daniel L. Kastner,Scott W. Canna
doi : 10.1002/art.41976
Volume 74, Issue 2 p. 353-357
Dominantly inherited PSTPIP1 mutations cause a spectrum of autoinflammatory manifestations epitomized by PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome.). The connections between PSTPIP1 and PAPA syndrome are poorly understood, although evidence suggests involvement of pyrin inflammasome activation. Interleukin-18 (IL-18) is an inflammasome-activated cytokine associated with susceptibility to macrophage activation syndrome (MAS). This study was undertaken to investigate an association of IL-18 with PAPA syndrome.
Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez,Katherine Pak,Albert Gil-Vila,Andres Baucells,Benjamin Plotz,Maria Casal-Dominguez,Assia Derfoul,Maria Angeles Martinez-Carretero,Albert Selva-O'Callaghan,Sara Sabbagh,Livia Casciola-Rosen,Jemima Albayda,Julie Paik,Eleni Tiniakou,Sonye K. Danoff,Thomas E. Lloyd,Frederick W. Miller,Lisa G. Rider,Lisa Christopher-Stine,Andrew L. Mammen,on behalf of the Childhood Myositis Heterogeneity Collaborative Study Group
doi : 10.1002/art.41931
Volume 74, Issue 2 p. 358-364
To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.
Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors
Dimitra Dimopoulou,Nikos Spyridis,George Vartzelis,Maria N. Tsolia,Despoina N. Maritsi
doi : 10.1002/art.41977
Volume 74, Issue 2 p. 365-366
Sjögren disease, not Sjögren's: comment on the article by Baer and Hammitt
Vincent Cottin
doi : 10.1002/art.41952
Volume 74, Issue 2 p. 366-367
Long-term risk of cancer development among anti-Th/To antibody–positive systemic sclerosis patients: comment on the article by Mecoli et al
Yuta Yamashita,Yoshinao Muro,Haruka Koizumi,Takuya Takeichi,Yasuhiko Yamano,Yasuhiro Kondoh,Masashi Akiyama
doi : 10.1002/art.41945
Volume 74, Issue 2 p. 368-369
VEXAS syndrome with systemic lupus erythematosus: expanding the spectrum of associated conditions
Aman Sharma,Gsrsnk Naidu,Prateek Deo,David B. Beck
doi : 10.1002/art.41957
Volume 74, Issue 2 p. 369-371
Long-term extension study of tofacitinib in refractory dermatomyositis
Julie J. Paik,Matthew Shneyderman,Laura Gutierrez-Alamillo,Jemima Albayda,Eleni Tiniakou,Jamie Perin,Grazyna Purwin,Sherry Leung,Doris Leung,Livia Casciola-Rosen,Andrew S. Koenig,Lisa Christopher-Stine
doi : 10.1002/art.41944
Volume 74, Issue 2 p. 371-372
